John Rhoden

John Rhoden currently serves as Executive Director at Eli Lilly and Company, leading genetic medicines ADME projects since March 2025. Prior to this role, John held positions as Head of Research at Matrisome Bio and Senior Director of Preclinical Development at Fusion Pharmaceuticals, where responsibilities included overseeing preclinical development with a focus on biologics in oncology, immuno-oncology, and autoimmunity. John's earlier experience at Eli Lilly included roles as Principal Research Scientist and Senior Research Scientist, emphasizing preclinical and translational ADME/PK/PD leadership. John's academic background includes a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from North Carolina State University.